SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A,Siegel R,Ward E,Hao Y,Xu J,Murray T,Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 7196.
  • 2
    Sampson E,Brierley JD,Le LW,Rotstein L,Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007; 110: 14516.
  • 3
    Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297306.
  • 4
    Mendelson J,Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33: 36985.
  • 5
    Ranson M,Hammond LA,Ferry D,Kris M,Tullo A,Murray PI,Miller V,Averbuch S,Ochs J,Morris C,Feyereislova A,Swaisland H, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20: 224050.
  • 6
    Shepherd FA,Rodrigues Pereira J,Ciuleanu T,Tan EH,Hirsh V,Thongprasert S,Campos D,Maoleekoonpiroj S,Smylie M,Martins R,van Kooten M,Dediu M, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 12332.
  • 7
    Lynch TJ,Bell DW,Sordella R,Gurubhagavatula S,Okimoto RA,Brannigan BW,Harris PL,Haserlat SM,Supko JG,Haluska FG,Louis DN,Christiani DC, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 212939.
  • 8
    Paez JG,Jänne PA,Lee JC,Tracy S,Greulich H,Gabriel S,Herman P,Kaye FJ,Lindeman N,Boggon TJ,Naoki K,Sasaki H, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497500.
  • 9
    Tsao MS,Sakurada A,Cutz JC,Zhu CQ,Kamel-Reid S,Squire J,Lorimer I,Zhang T,Liu N,Daneshmand M,Marrano P,Santos GC, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 13344.
  • 10
    Hirsch FR,Varella-Garcia M,Bunn PA,Jr,Franklin WA,Dziadziuszko R,Thacher N,Chang R,Parikh P,Pereira JR,Ciuleanu T,von Pawel J,Watkins C, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 503442.
  • 11
    Cappuzzo F,Hirsch FR,Rossi E,Bartolini S,Ceresoli GL,Bemis L,Haney J,Witta S,Danenberg K,Domenichini I,Ludovini V,Maqrini E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 64355.
  • 12
    Davis H,Bignell GR,Cox C,Stephens P,Edkins S,Clegg S,Teague J,Woffendin H,Garnett MJ,Bottomley W,Davis N,Dicks E, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 94954.
  • 13
    Kimura ET,Nikiforova MN,Zhu Z,Knauf JA,Nikiforov YE,Fagin JA. High prevalence of BRAF mutaions in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 14547.
  • 14
    Cohen Y,Xing M,Mambo E,Guo Z,Wu G,Trink B,Beller U,Westra WH,Ladenson PW,Sidransky D. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95: 6257.
  • 15
    Therasse P,Arbuck SG,Eisenhauer EA,Wanders J,Kaplan RS,Rubinstein L,Verweij J,van Glabbeke M,van Oosterom AT,Christian MC,Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 20516.
  • 16
    Nagai Y,Miyazawa H,Huqun,Tanaka T,Udagawa K,Kato M,Fukuyama S,Yokote A,Kobayashi K,Kanazawa M,Hagiwara K. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005; 65: 727682.
  • 17
    Kosaka T,Yatabe Y,Endoh H,Kuwano H,Takahashi T,Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 891923.
  • 18
    Hirsch FR,Varella-Garcia M,Bunn PA,Jr,Di Maria MV,Veve R,Bremmes RM,Barón AE,Zenq C,Franklin WA. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 2003; 21: 3798807.
  • 19
    Sharma SV,Bell DW,Settleman J,Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 16981.
  • 20
    Ciardiello F,Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 116074.
  • 21
    Amann J,Kalyankrishna S,Massion PP,Ohm JE,Girard L,Shigematsu H,Peyton M,Juroske D,Huang Y,Stuart Salmon J,Kim YH,Pollack JR, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005; 65: 22635.
  • 22
    Sordella R,Bell DW,Haber DA,Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 11637.
  • 23
    Maeda Y,Davé V,Whitsett JA. Transcriptional control of lung morphogenesis. Physiol Rev 2007; 87: 21944.
  • 24
    Mclnnes RR,Michaud J. Development of the thyroid gland: lessons from congenitally hypothyroid mice and men. Clin Genet 2003; 63: 44555.
  • 25
    Mitsiades CS,Kotoula V,Poulaki V,Sozopoulos E,Negri J,Charalambous E,Fanourakis G,Voutsinas G,Tseleni-Balafouta S,Mitsiades N. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 2006; 91: 36626.
  • 26
    Lee DH,Lee GK,Kong S-Y,Kook MC,Yang SK,Park SY,Park SH,Keam B,Park DJ,Cho BY,Kim SW,Chung K-W, et al. Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol 2007; 60: 8814.
  • 27
    Iribarren C,Haselkorn T,Tekawa IS,Friedman GD. Cohort study of thyroid cancer in a San Francisco bay area population. Int J Cancer 2001; 93: 74550.
  • 28
    Eberhard DA,Giaccone G,Johnson BE. Non-small-cell lung cancer working group. Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: standardization for use in the clinical trial setting. J Clin Oncol 2008; 26: 98394.
  • 29
    Fusco A,Grieco M,Santoro M,Berlingieri MT,Pilotti S,Pierotti MA,Della Porta G,Vecchio G. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987; 328: 1702.
  • 30
    Grieco M,Santoro M,Berlingieri MT,Melillo RM,Donghi R,Bongarzone I,Pierotti MA,Della Porta G,Fusco A,Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinoma. Cell 1990; 60: 55763.
  • 31
    Zhu Z,Ciampi R,Nikiforva MN,Gandhi M,Nikiforov YE. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 2006; 91: 360310.